hypothyroidism negatively impacts survival (3, 4) . Previous studies evaluating the associations between subclinical hypothyroidism and mortality have yielded conflicting results, likely due to the heterogeneity of patient populations within and across studies (4 -17) .
Emerging data suggest these associations may be dependent upon underlying cardiovascular risk. Whereas studies in populations with high underlying cardiovascular risk (eg, patients at high risk for or who had recent cardiac events) have observed that subclinical hypothyroidism is associated with greater all-cause and cardiovascular mortality (9, 11, 12) , this has not been observed in lower-risk groups (5-8, 14, 16) . In a previous metaanalysis, the association between subclinical hypothyroidism and mortality did not differ among patients with and without underlying cardiovascular disease (18) , whereas in a subsequent meta-analysis, pre-existing congestive heart failure (CHF) was observed to modify the association between subclinical hypothyroidism and CHF events (19) . Given hypothyroidism's impact on cardiac contractility, systemic vascular resistance, electrophysiologic irritability, and atherosclerosis (20, 21) , it has been speculated that subclinical hypothyroidism might predispose to death from cardiac causes. It is plausible that subpopulations with CHF may be predisposed to cardiac morbidity and mortality associated with subclinical hypothyroidism, owing to underlying distortions in ventricular architecture that confer heightened susceptibility to hypothyroid-related perturbations (22) .
Thyrotropin (commonly referred to as thyroid stimulating hormone; TSH) is considered the most sensitive and specific biochemical metric of thyroid function (23) . In subclinical hypothyroidism, serum TSH is elevated in the context of normal thyroxine (T 4 ) levels. Notably, previous studies have also shown that median TSH levels are lower in Blacks than among persons of other races (1, 24 -27) , perhaps owing to a different physiological set point (28) . Therefore, it is plausible that the hypothalamic-pituitarythyroid axis may be intrinsically different in Blacks vs nonBlacks. There have been conflicting results in regard to the differential association between subclinical hypothyroidism and outcomes across racial groups in the aforementioned meta-analyses. Whereas there appeared to be greater risk of coronary heart disease (CHD) events in Whites compared with Blacks (18) , modification by race was not observed for CHF events, CHD mortality, or allcause mortality (18, 19) . Given the low representation of Blacks, analyses may have been underpowered to detect interaction by race.
We hypothesized that the association between subclinical hypothyroidism and mortality differs according to CHF and race. We conducted the following study to examine whether the association between 1) subclinical hypothyroidism and 2) hypothyroidism overall with mortality is modified by concomitant CHF and race using a large, nationally representative sample of the U.S. adult population from the Third National Health and Nutrition Examination Survey (NHANES III) with detailed laboratory data and extended follow-up over which to observe outcomes.
Subjects and Methods

Source cohort
We conducted a retrospective cohort study using data from the NHANES III, a survey executed by the National Center for Health Statistics (NCHS) from 1998 to 1994 to provide national estimates of the health and nutritional status of U.S. children and adults. The survey employed a complex, multistage, stratified, clustered sampling design in which children, elderly, Black, and Mexican-American participants were oversampled to enable precise estimation within these subgroups (29) . At the time of enrollment, participants' self-reported sociodemographics, comorbid conditions, and medications were assessed; blood and urine samples were collected for measurement of serum TSH, total T 4 (TT 4 ), creatinine, and urine albumin and creatinine (details below). The NHANES III study protocol was approved by the NCHS Institutional Review Board, and all participants gave their informed written consent before participation. The current study was deemed exempt by the Partners Healthcare Institutional Review Board.
We included NHANES III participants ages Ն18 years old at enrollment, who had baseline serum TSH, TT 4 , and creatinine measurements and had available follow-up data (n ϭ 15 467). From these, we excluded participants with secondary hypothyroidism (TSH Ͻ lower limit of normal [LLN] and TT 4 Ͻ LLN) (30) due to sparse representation (n ϭ 2). Given that the comparison of interest was between primary hypothyroidism (subclinical and overall) vs euthyroidism with mortality within strata of CHF and race, we excluded participants with primary hyperthyroidism (TSH Ͻ LLN; n ϭ 560), secondary hyperthyroidism (TSH Ͼ upper limit of normal ͓ULN͔ and TT 4 Ͼ ULN; n ϭ 8) (30) , and missing data on CHF status (n ϭ 18); race was not missing for any patients. The final analytical cohort contained 14 879 participants. Within the NHANES III, race and comorbidity status (including CHF) were self-identified by participants.
Laboratory measures
TSH was measured with a chemiluminescence immunometric assay (Nichols Institute Diagnostics, San Juan Capistrano, California), and TT 4 was measured with an RIA (Roche Molecular Biochemicals, Indianapolis, Indiana). The normal reference ranges for TSH and TT 4 were 0.39 to 4.6 mIU/L and 4.5 to 13.2 g/dL, respectively (1, 31) . Spot urine albumin was measured by solid-phase fluorescent immunoassay, and spot urine and serum creatinine were measured by the Jaffe rate reaction (31) . Microalbuminuria and macroalbuminuria were defined as an albumin to creatinine ratio (ACR) of 30 to 299 mg/g and Ն300 mg/g, respectively (32) . Serum creatinine measurements were calibrated to the Cleveland Clinic laboratory by subtracting 0.23 mg/dL as previously described (33 
Exposure ascertainment
In co-primary analyses, we sought to examine how mortality was associated with hypothyroidism overall and with subclinical hypothyroidism. In the former analyses, participants with TSH higher than ULN were considered hypothyroid, and participants with TSH within the reference range were considered euthyroid. In the latter analyses, hypothyroid participants were parsed into subclinical and overt disease on the basis of their TT 4 levels (subclinical is within reference range; overt is below LLN) (30) . Given that TT 4 levels may not be concordant with unbound, biologically active free T 4 levels (35), secondary analyses were also conducted in which subclinical and overt hypothyroidism were defined by severity of TSH derangement (subclinical is Յ10 mIU/L; overt is Ͼ10 mIU/L); this cutoff was selected based on the TSH threshold at which treatment of subclinical hypothyroidism is often recommended based on published guidelines (36) .
Outcome ascertainment
The primary outcome of interest was all-cause mortality. Mortality data were available through December 31, 2006, and were ascertained through linkage of NHANES III to death certificate data from the National Death Index (NDI). The NDI is a central computerized index of annually updated death record information compiled from data submitted by state vital statistics offices to the NCHS. The NDI is considered the gold standard for death ascertainment for epidemiologic research, because it has been shown to provide superior coverage of deaths compared with other sources (37) . Participants were considered at risk the day after baseline TSH and TT 4 measurements until death or end of follow-up. Secondary analyses considered death from cardiovascular causes; this was ascribed on the basis of International Statistical Classification of Diseases, Injuries, and Causes of Death codes, 10th revision codes (Supplemental Table  1 , published on The Endocrine Society's Journals Online web site at http://jcem.endojournals.org) (38, 39) . Cause-of-death information was available for 98.8% of the source cohort.
Statistical analyses
Baseline characteristics between exposure groups were compared using 2-sample t tests, Wilcoxon rank sum tests, and tests as dictated by data type. Analogous methods were used to estimate associations between exposure and mortality in all analyses. Unadjusted associations between exposure and mortality were estimated using Kaplan-Meier plots, log-rank testing, and unadjusted Cox proportional hazards models. Multivariable Cox proportional hazards models were adjusted for potential confounders of the exposure-mortality association based on published data that included age, sex, categories of race/ethnicity (non-Hispanic Black and non-Hispanic White referred to as Black and White, respectively, in this report; Mexican-American; and other race/ethnicity), diabetes, active smoking status, hypertension, hypercholesterolemia, previous stroke, previous myocardial infarction (MI), pre-existing CHF, body mass index (BMI), ACR (categorized as Ͻ30, 30 -299, or Ն300 mg/g or missing), and eGFR (categorized as Ͻ60 or Ն60 mL/min/1.73 m 2 ). Sensitivity analyses were also conducted in which 1) multivariable Cox models were additionally adjusted for cardiovascular medications (amiodarone, angiotensin-converting enzyme ͓ACE͔ inhibitors, ␤-blockers, dihydropyridine and nondihydropyridine calcium channel blockers, digoxin, thiazide and loop diuretics, statins, niacin, gemfibrozil, and long-acting nitrates) and 2) participants on baseline thyroid supplementation (n ϭ 260) and thyroid-suppressive therapy (n ϭ 3) were excluded. The proportional hazards assumption was confirmed graphically and through Schoenfeld residual testing.
Stratum-specific estimates were estimated within subgroups defined by race, pre-existing CHF, and pre-existing atherosclerotic disease (previous MI or stroke). Statistical significance of effect modification was assessed by likelihood ratio testing comparing models with and without the corresponding 2-way factorby-exposure cross-product terms (eg, CHF ϫ subclinical hypothyroidism). An interaction P value of Ͻ.05 was considered statistically significant. Analyses were performed using Stata MP version 10.1 (StataCorp, College Station, Texas).
Results
Cohort description
The overall study cohort consisted of 14 879 participants, 14 130 (95.0%) of whom were euthyroid and 749 (5.0%) of whom had hypothyroidism overall; among the latter, 691 had subclinical hypothyroidism (representing 4.6% of the total cohort and 92.3% of participants with hypothyroidism overall). Compared with euthyroidism, participants with subclinical hypothyroidism tended to be older, female, and White; had higher prevalence of low eGFR, diabetes, micro-and macroalbuminuria, CHF, hypertension, hypercholesterolemia, previous stroke, previous MI, higher BMI, and exogenous thyroid hormone use; and had a lower prevalence of smoking (Table 1) . Similar patterns of association were observed when comparing patients with hypothyroidism overall with euthyroidism (Table 1) and when comparing subclinical hypothyroidism as defined by TSH levels with euthyroidism (Supplemental Table 2 ).
Subclinical hypothyroidism and mortality according to pre-existing CHF
Within the overall cohort, participants contributed a total of 199 299 patient-years of at-risk time during which 3337 all-cause deaths (1477 cardiovascular deaths) were observed. Median time at risk was 14.3 years. In the overall cohort, a significant association between subclinical hypothyroidism and hypothyroidism overall with allcause mortality was not observed: adjusted hazard ratios (aHRs) ϭ 1.04 (with 95% confidence interval [CI] of 0.91-1.18) and 1.02 (95% CI, 0.90 -1.15), respectively. Figure 1B ). In sensitivity analyses adjusted for cardiovascular medications, results were qualitatively similar (Table 2) . After exclusion of participants using baseline thyroid medications, associations between subclinical hypothyroidism and hypothyroidism overall with mortality in participants with pre-existing CHF were even more potent (Table 2) . A similar pattern of results was observed in secondary analyses of subclinical hypothyroidism defined by TSH levels only. Subclinical hypothyroidism was significantly associated with greater all-cause mortality compared with euthyroidism in those with CHF (aHR ϭ 1.77 [95% CI, 1.19 -2.64]) but not in those without CHF (aHR ϭ 0.97 [95% CI, 0.84 -1.12]) (P interaction ϭ .01; Supplemental Figure 1 ). In sensitivity analyses adjusted for cardiovascular medications, results were qualitatively similar (Table 2). After exclusion of participants using baseline thyroid medications, the association between subclinical hypothyroidism with mortality in participants with preexisting CHF was even more potent (Table 2) .
Hypothyroidism overall and mortality according to race
Race modified the association between hypothyroidism overall with all-cause mortality (P interaction ϭ .03).
Hypothyroidism overall was significantly associated with greater all-cause mortality compared with euthyroidism in Black participants (aHR ϭ 1.44 [95% CI, 1.03-2.03) but not in those who were non-Black (aHR ϭ 0.95 [95% CI, 0.83-1.08) ( Figure 2B ). In sensitivity analyses adjusted for cardiovascular medications, results were qualitatively similar ( Table 2 ). After exclusion of participants using baseline thyroid medications, the association between hypothyroidism overall with mortality in Black participants was even more potent (Table 2) .
In stratified analyses, subclinical hypothyroidism was associated with greater all-cause mortality compared with euthyroidism in Black participants (HR 1.51 [95% CI, 1.05-2.17) but not in other races (HR ϭ 0.96 [95% CI, 0.84 -1.10]); however, tests of interaction (P interaction ϭ .07) did not reach statistical significance (Figure 2A ). In sensitivity analyses adjusted for cardiovascular medications, results were qualitatively similar ( Table 2) . After exclusion of participants using baseline thyroid medications, tests of interaction for race were statistically significant (P interaction ϭ .005) ( Table 2) .
Similarly, in stratified analyses, subclinical hypothyroidism defined by TSH levels trended toward greater allcause mortality only among Black participants (aHR ϭ 1.48 [95% CI, 0.96 -2.28]), but not in those of other races (aHR ϭ 0.98 [95% CI, 0.85-1.14]); however, estimates and tests for interaction did not reach statistical significance (P interaction ϭ .08; Supplemental Figure 2 ). In sensitivity analyses adjusted for cardiovascular medications, results were qualitatively similar. After exclusion of participants using baseline thyroid medications, tests of interaction for race were statistically significant (P interaction ϭ .03) ( Table 2) .
Subclinical hypothyroidism and mortality considering both pre-existing CHF and race
The concurrent effects of race and CHF on the association between subclinical hypothyroidism and hypothy- roidism overall with all-cause mortality were considered (Table 3) . Among participants without CHF, race modified the association between subclinical hypothyroidism and mortality: aHR (95% CI) was 1.43 (0.96 -2.14) among Blacks and 0.89 (0.77-1.03) among non-Blacks (P interaction ϭ .002). Similarly, among participants with CHF, race modified the association between subclinical hypothyroidism and mortality; aHR (95% CI) was 2.68 (0.84 -8.61) among Blacks and 1.36 (0.92-2.02) among non-Blacks (P interaction ϭ .03).
Among participants without CHF, race modified the association between hypothyroidism overall and all-cause mortality; aHR (95% CI) was 1.55 (1.06 -2.27) among Blacks and 0.87 (0.75-1.00) among non-Blacks (P interaction ϭ .005). In contrast, among participants with CHF, hypothyroidism overall was associated with elevated risk that did not differ according to race (P interaction ϭ .7).
When cardiovascular mortality was considered (Table  4) , race modified the association between subclinical hypothyroidism and mortality among participants without CHF (P interaction ϭ .01) but not among participants with CHF (P interaction Ͼ 0.9). Similarly, race modified the association between hypothyroidism overall and mortality among participants without CHF (P interaction ϭ .004) but not among participants with CHF (P interaction ϭ .4).
Subclinical hypothyroidism and mortality according to pre-existing atherosclerotic disease
In stratified analyses, subclinical hypothyroidism was associated greater all-cause mortality compared with euthyroidism in participants with atherosclerotic disease (aHR ϭ 1.34 [95% CI, 1.04 -1.74]) but not in those without (aHR ϭ 0.91 [95% CI, 0.73-1.14]); however, tests of interaction did not reach statistical significance (P interaction ϭ .2). Subclinical hypothyroidism defined by TSH levels was also associated with greater all-cause mortality compared with euthyroidism in participants with atherosclerotic disease but not in those without (aHR ϭ 1.32 [95% CI, 1.00 -1.75] and 0.96 [95% CI, 0.82-1.13], respectively); however, tests of interaction did not reach statistical significance (P interaction ϭ .2). Similarly, hypothyroidism overall was associated with greater all-cause mortality compared with euthyroidism in participants with atherosclerotic disease but not in those without (aHR ϭ 1.30 [95% CI, 1.02-1.66] and 0.93 [95% CI, 0.81-1.08]); however, tests of interaction did not reach statistical significance (P interaction ϭ .08).
Discussion
In this large, nationally representative sample of U.S. adults, we observed that pre-existing CHF was an important modifier of the association between subclinical hypothyroidism and hypothyroidism overall with mortality. Subclinical hypothyroidism and hypothyroidism overall were each associated with greater all-cause mortality in those with CHF, but not in those without. Additionally, race modified the association between hypothyroidism overall with mortality; hypothyroidism overall was associated with greater all-cause mortality in Blacks but not in other races. These findings were robust across multiple secondary analyses as well as sensitivity analyses that adjusted for cardiovascular medications and excluded participants on baseline thyroid medications. When race and CHF were considered concurrently, we observed that sub- Figure 1 . Comparison of the association between subclinical hypothyroidism (TSH higher than ULN; TT 4 within reference range) (A) and hypothyroidism overall (TSH higher than ULN) (B) vs euthyroidism (TSH within reference range) with all-cause mortality, stratified by preexisting CHF status. Analyses were adjusted for age, sex, race/ethnicity, diabetes, smoking, hypertension, hypercholesterolemia, previous stroke, previous MI, BMI, ACR, and eGFR (specification for each as per Table 1 ). Statistical significance of effect modification was assessed by likelihood ratio testing. clinical hypothyroidism and hypothyroidism overall were associated with greater mortality in the context of Black race, CHF, or both. There has been ongoing debate as to whether subclinical hypothyroidism, considered to be a milder form of hypothyroidism, adversely impacts survival (3, 4) . There is plausible reason to suspect that subclinical hypothyroidism is causally associated with greater mortality risk. Previous data have suggested that subclinical hypothyroidism is associated with ischemic heart disease (13), CHF (14) , accelerated coronary atherogenesis (40) , and cardiac conduction abnormalities (41) that may predispose to malignant ventricular arrhythmias. Nonetheless, previous studies that directly examined the associations of subclinical hypothyroidism with all-cause and cardiovascular mortality have yielded mixed results (4 -8, 10 -17).
Studies in patients of average underlying cardiovascular risk have tended to be negative (5-8, 14, 16) , whereas those in patients at high cardiovascular risk have tended to be positive (9, 11, 12) . Two meta-analyses have sought to examine this issue more systematically. The first, by Gencer et al (19) , indicated that subclinical hypothyroidism was associated with a greater risk of heart failure events among patients with pre-existing CHF but not among those without. The directionality of the association was similar to that seen in this study; however, interaction tests did not reach statistical significance, and the study did not consider survival as an outcome. The second, by Rodondi et al (18) , examined for but did not detect a differential association of subclinical hypothyroidism with CHD events and mortality among patients who did and did not have any form of pre-existing cardiovascular a Adjusted for age, sex, race (omitted from models stratified on race), diabetes, smoking, hypertension, hypercholesterolemia, previous stroke, previous MI, pre-existing CHF (omitted from models stratified on CHF), BMI, ACR, and eGFR. b Adjusted for all covariates in multivariable-adjusted model as well as amiodarone, ACE inhibitors, ␤-blockers, calcium channel blockers (dihydropyridine and nondihydropyridine), digoxin, thiazide and loop diuretics, antihyperlipidemics (statins, niacin, and gemfibrozil), and longacting nitrates. c Participants on baseline thyroid supplementation and suppressive therapy excluded; adjusted for all covariates in multivariable-adjusted model.
disease. One possibility is that subclinical hypothyroidism poses unique risk among patients with CHF, possibly related to consequent alterations in neurohormonal activation, ventricular remodeling, cardiac contractility, and vascular tone, but not those with other forms of cardiovascular disease. Therefore, when CHF is subsumed into a broader category of heart disease, other types of which do not interact with subclinical hypothyroidism, effect modification by heart failure is diluted and not observed.
To our knowledge, ours is the first study to observe that CHF modifies the association between subclinical hypothyroidism and hypothyroidism overall with all-cause mortality among nonhospitalized patients. In the overall cohort, we did not observe significant associations between either subclinical hypothyroidism or hypothyroidism overall with mortality. However, in stratified analyses, both were associated with greater death risk in those with CHF but not in those without. It is possible that the pooled (nonstratified) analysis masked important subgroup effects. Given that most NHANES III participants did not have pre-existing CHF, analyses of the population as a whole may have been dominated by effects among those without CHF. Given the compensatory alterations in neurohormonal activation, ventricular remodeling, cardiac contractility, and vascular tone required to maintain cardiac output in structural heart disease (22) , it is plausible that participants with pre-existing CHF may have a lower reserve with which to tolerate the acute hemodynamic, volume, and electrophysiologic changes associated with subclinical hypothyroidism, with subsequent implications on mortality.
This is also the first study to observe that Blacks have a greater mortality risk related to hypothyroidism compared with other races. For reasons not yet fully elucidated, epidemiologic studies have shown that Blacks have a lower median TSH and distribution compared with Whites (24 -27); thus, definitions of hypothyroidism using standard TSH reference ranges indicate that Blacks have a lower prevalence of hypothyroidism. It has been suggested that there may be misclassification of thyroid functional disease among Blacks on this basis and that race-based reference ranges should be considered (28, 42) . Two of the aforementioned meta-analyses comparing the association between subclinical hypothyroidism and outcomes across racial groups have shown conflicting results (18, 19) . Rodondi et al (18) found that subclinical hypothyroidism was associated with increased CHD events in Whites but not among Blacks; neither meta-analysis observed effect modification by race for CHF events or mortality (18, 19) . In contrast, we observed that hypothyroidism was associated with greater mortality among Blacks but not among non-Blacks, which was consistent across multiple sensitivity analyses. The larger representation of Blacks in our cohort compared with previous studies may have provided greater power to detect interaction by race. Additional studies are needed to confirm this finding and to explore potential genetic, biologic, socioeconomic, and psychosocial factors that may explain differential racial susceptibility.
Our study has several strengths, including its large sample size, large representation of Black participants, extended follow-up period, comprehensive availability of thyroid functional test data, and robustness of findings across analytical strategies. However, several limitations of our study bear mention. First, thyroid functional disease categorizations were based on one-time measure- Comparison of the association between subclinical hypothyroidism (TSH higher than ULN; TT 4 within reference range) (A) and hypothyroidism overall (TSH higher than ULN) (B) vs euthyroidism (TSH within reference range) with all-cause mortality, stratified by race (Black vs non-Black). Analyses were adjusted for age, sex, diabetes, smoking, hypertension, hypercholesterolemia, previous stroke, previous MI, pre-existing CHF, BMI, ACR, and eGFR (specification for each as per Table 1 ). Statistical significance of effect modification was assessed by likelihood ratio testing. ments of TSH with or without TT 4 and were therefore subject to misclassification. In healthy ambulatory patients, TSH is typically maintained in a narrow range over time (ie, variation of 0.5 mIU/L when measured monthly over a 1-year period) (43, 44) . Nonetheless, we cannot exclude the possibility that, in some patients studied here, TSH deviated from its normal set point on the basis of nonthyroidal illness. Most commonly, TSH falls in response to systemic illness; resultant bias should therefore favor patients with higher TSH levels and would render conservative the observed association between hypothyroidism and death. However, because TSH was not measured longitudinally, we cannot exclude the possibility that there was misclassification bias in the opposite direction. Second, direct thyroid hormone measurements in NHANES III used TT 4 levels in lieu of free T 4 levels, with the former measurements subject to thyroid functional status misclassification on the basis of differential levels of thyroid-binding globulin or differential T 4 protein binding (35) . Thus, we employed two definitions of subclinical hypothyroidism (based on concurrent TSH/TT 4 levels vs TSH levels only) that yielded essentially the same findings. Third, CHF status was self-identified as opposed to using objective measurements (ie, echocardiography), which may have identified a subset with more severe disease. It is also possible that self-report of CHF status may have resulted in misclassification of disease, such that participants with other types of cardiovascular disease (ie, atherosclerosis) may have identified themselves as having CHF. Lastly, as with all observational studies, we cannot exclude the possibility of residual confounding.
In conclusion, our findings demonstrated that subclinical hypothyroidism, as well as hypothyroidism overall, are associated with a greater risk of mortality in subpopulations with pre-existing CHF and of Black race. These findings bear particular relevance given the high prevalence of hypothyroidism and CHF and the racial/ethnic diversity of the U.S. population. At this stage, additional studies are needed to confirm findings; to elaborate underlying genetic, biologic, and environmental determinants of hypothyroidism and its associated complications across racial/ethnic groups; and to examine the differential therapeutic effectiveness and safety of thyroid hormone supplementation for subclinical hypothyroidism and hypothyroidism overall vis-à-vis effects on survival according to race/ethnicity and underlying cardiovascular risk. 
